We have investigated metallothionein (MT) I and II mRNA and protein in B-cell lymphomas with particular reference to diffuse large B-cell lymphoma (DLBCL). The mRNA profiling was performed on Affymetrix arrays and showed upregulated MT mRNA in 15 of 48 DLBCL, including 12 of 23 ABC and 3 of 9 type-3 lesions. By contrast MT mRNA was low to undetectable in 16 GCB-type DLBCL. Only one of 15 patients with upregulated MT mRNA achieved a sustained remission, suggesting that upregulated MT mRNA constitutes a significant risk factor for treatment failure. This was confirmed in two independent series (Rosenwald et 
Introduction
The metallothioneins (MT) are low molecular weight (6-7 kD) non-enzymatic proteins consisting of 60-68 amino acids. Four subtypes are recognized (MTI-IV). Among these MT-I and MT-II are the major forms.
They are encoded by genes located on the same chromosome (no. 16 in humans), they are regulated and expressed co-ordinately and their distribution and biological functions are analogous. 1,2 Both proteins contain 2 globular, cystein rich domains, which can bind essential and toxic metals, such as zinc, copper, cadmium and mercury. A main function is to act as an intracellular zinc reservoir. 3 Furthermore, there are indications that the MT are also involved in the protection against DNA damage, oxidative stress and apoptosis. 1, [4] [5] [6] Several observations have indicated that altered MT expression is important for diseases in humans, including cancer which often upregulates MT compared to normal cells. 5, 7, 8 Moreover, increased MT levels have been associated with high-grade histology and an aggressive behavior in several of types of cancer. 5, [9] [10] [11] So far most studies of MT in malignant diseases have been performed in epithelial tumours. Very limited information is available about the expression of MT in lymphomas. In this study we have investigated 141 B-cell lymphomas for MT protein expression by immunohistology. Furthermore, MT mRNA levels were investigated by expression profiling in 48 DLBCL previously classified into three groups (GCB, ABC and type-3) on Affymetrix arrays. The results indicate that increased MT mRNA and protein may constitute an independent risk factor in DLBCL.
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From penhagen. An additional 10 cases were kindly made available from the Department of Pathology, Odense University Hospital. Only specimens obtained at diagnosis, prior to treatment were included. All cases were reviewed by histology and immunohistology using standard panels of antibodies, i.e. CD20, CD79a, CD10, CD21, CD23, CD3, CD5, Bcl-2 and cyclin D1. The samples were then classified in accordance with the WHO (2001) and comprised 115 diffuse large B-cell lymphomas (DLBCL), 11 follicular lymphomas (FL), 2 mantle cell lymphomas (MCL), 7 small lymphocytic lymphomas (SLL) and 6 cases of multiple myeloma (MM). Of the DLBCL 86 were primary nodal and 29 were primary extranodal at presentation with involvement of the tonsil (8 cases), salivary glands (4 cases), thyroid (3 cases), testis (3 cases), bone (2 cases), nasal cavity (1 case), cervix uteri (1 case), liver (1 case), breast (1 case), kidney (1 case), pericardium (1 case), rhinopharynx (1 case) and skin (1 case).
Clinical data, survival
The clinical records were reviewed in all of the DLBCL patients with particular reference to age, site of initial involvement, stage at diagnosis, response to treatment and survival. Information on the International Prognostic Index (IPI) could be retrieved in 74 of the cases. All patients were treated using anthracyclin based regimens (CHOP or CHOP-like), supplemented in six patients with additional antibody-therapy (e.g. Rituximab). Survival was calculated from the day of diagnosis until death or the date of last follow-up. Overall survival duration curves were plotted according to the Kaplan and Meier method. 12 The log-rank test was used to assess the differences between the survival curves and nominal P-values were calculated.
Group comparisons were done using two-sided, paired students T-test (equal variance assumed).
Immunohistology
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Sections of formalin-fixed, paraffin-embedded biopsies were heated in a Milestone Micromed microwave oven in citrate buffer (pH: 6) for 15 min., incubated 60 minutes at room temperature with a 1:40 dilution of DAKO-MT (clone: E9) reactive with MT-I and MT-II in routinely processed histological samples 13 and stained in the Techmate 500 Immunostainer, using the DAKO Envision K5007 as a secondary antibody.
Since the results suggested that some of the MT-positive cells represented macrophages, samples were also stained using CD68 (PGM1) on adjacent sections.
As a preliminary approach to scoring, all specimens were screened by two authors (CBP, ER) to obtain an overall impression of the reactivity patterns. Furthermore, in 20 randomly selected DLBCL, the number of MT-positive tumour cells was counted in 10 representative areas at 400 times magnification. These results showed that four broad categories could be distinguished, i.e. no/occasional (< 5%); few (5-20%); moderate Controls were included in all experiments and consisted of autopsy specimens of normal liver and kidney.
In these controls, strong staining was seen of both nuclei and cytoplasm in proximal tubuli and hepatocytes.
mRNA expression profiling
Frozen tissue kept at -80 o C was available from 48 of the DLBCL and was subjected to expression profiling as described. 14 Briefly, from each case, 5 micrograms of purified RNA was used to generate biotin-labeled antisense cRNA. After fragmentation at 94°C for 35 min., the labeled cRNA samples were hybridized for 16
hours to Affymetrix HG-U133A arrays (Affymetrix Inc.), washed and stained with phycoerytrin conjugated streptavidin (SAPE) and scanned in the Affymetrix GeneArray® 2500 scanner to generate fluorescent images. All of the above as described in the Affymetrix GeneChip® protocol. The image files (cel files) were
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From imported into the software package DNA-Chip Analyzer (C. Li and W.H. Wong (www.dchip.org)). The array files were normalized and expression values calculated as described. 14 Samples were categorized as being GCB, ABC and type-3 by hierarchical clustering using a list of 78 classifier genes, as already published. 15 For validation, data from two independent studies of 240 newly diagnosed DLBCL analyzed on the Lymphochip platform 16 and 176 newly diagnosed DLBCL with available Affymetrix HU133 A+B data sets 17 For personal use only. on September 13, 2017. by guest www.bloodjournal.org From
Results

MT mRNA expression in DLBCL
mRNA extracted from frozen tissues from 48 of the DLBCL was examined by global expression profiling on Affymetrix arrays. Similar to other reports, [18] [19] [20] the tumours could be grouped into 3 categories depending upon the differential expression of 78 genes as described in our previously developed classifier model, i.e. GCB (n=16), ABC (n=23) and type-3 (n=9). 15 A further analysis of other genes differentially expressed in these groups showed that the genes encoding mRNA MT-IIa and the different isoforms of MT-I (e.g. MT-IL,G,H,X,G,F,E,K) were upregulated (above mean) in 12 of 23 of the ABC tumours and in 3 of 9 type-3 tumours, but were low to undetectable in the 16 GCB lesions (see Fig. 1 A+B). A correlation with the treatment outcome showed that only one of 15 patients with upregulated MT mRNA achieved a sustained complete remission (CR). The remaining either showed only a temporary response (n=4) or had refractory disease (n=10). Conversely, in the 33 patients with low MT mRNA levels, 17 achieved a sustained CR, 9 achieved a temporary CR but relapsed, and 7 had refractory disease. These data suggested that upregulated MT mRNA may identify a particular subgroup of ABC and type-3 DLBCL with a poor response to conventional chemotherapy and a potentially aggressive behavior.
To address this possibility in more detail, the survival of patients with high vs. low MT mRNA was investigated both in this series and in another two, independent data sets (Rosenwald et al. 16 and Monti et al. 17 ).
In our series of 48 patients, a tendency was seen towards an inferior survival in patients with high MT mRNA compared to those with low MT mRNA ( Fig. 2A) . However, this difference did not reach statistical significance, presumably due to the relatively small number of patients. By contrast, among 238 patients downloaded from the publication of Rosenwald et al, 16 those with high (above mean) MT-IIa mRNA showed a significantly poorer survival than those with lower MT-IIa levels (Fig. 2B) . A similar difference (p=0,05) was observed when data from 130 patients from the study by Monti et al. 17 were analyzed (data not shown).
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MT protein expression
To characterize MT expression at the protein level, an extended series of pre-treatment, diagnostic biopsies from 141 B-cell lymphomas sampled during the period 1982-2004 were examined by immunohistology using anti-MT antibody (E9) reactive with MT-I and MT-II in formalin fixed specimens. 13 This series included the 48 DLBCL described above as well as samples from an additional 67 DLBCL. Furthermore, specimens from 20 small B-cell lymphomas (see Material and Methods) and 6 multiple myelomas were investigated.
In all the B-cell lymphomas, the antibody stained a population of CD68-positive, dendritic cells, representing tumour infiltrating macrophages (Fig. 3) . MT labeling of the macrophages was prominent in the cytoplasm, but the nuclei were also weakly stained in most cases. The number of MT-positive tumour infiltrating macrophages was most abundant in DLBCL (Table 1) , but had no impact on the 5-year survival (Fig. 4) .
MT expression by the lymphoma cells was more restricted. As shown in Table 2 (Table 3) . However, the survival at 5 years was significant poorer in the former category (Fig. 6) , suggesting that > 20% MT-positive lymphoma cells constitutes an independent risk factor in DLBCL. Small, reactive, tumour infiltrating lymphocytes were MT-negative (Fig. 5) .
Correlation between the number of MT-positive tumour cells and macrophages in individual DLBCL is summarized in Table 4 . As shown no specific correlation was identified. 
MT mRNA vs. protein expression
MT-II and the several different isoforms of MT-I are co-ordinately expressed under a number of conditions. 1, 23 This was also seen in our study, as illustrated in For personal use only. on September 13, 2017. by guest www.bloodjournal.org From
Discussion
The MT are single chain 6-7 kD proteins with a high content of cystein, sulfur and metal. Four subtypes are recognized in humans, MT-I and MT-II, which are widespread, and MT-III and MT-IV, which are more restricted in distribution. All the MT contain 2 metal binding domains, a C-terminal α and a N-terminal β domain. Both are rich in cysteins, which can bind essential and toxic metals. The MT genes are located on chromosome 16 in humans and can be activated by a variety of stimuli, including metal ions, oxidative stress, cytokines, glucocorticoids, growth factors and hypoxia. 2, 8, 21, 22 The MT have established roles in metal homeostasis and in the protection against reactive oxygen species. Furthermore, there are indications that the MT are involved in cell proliferation, in the protections against DNA damage, in the prevention of apoptosis and in the acquisition of resistance to a variety of commonly used cancer chemotherapies. 8, [21] [22] [23] [24] Accordingly, it is conceivable that altered MT expression may play a role for neoplastic disorders.
Expression of the MT have been studied in considerable detail in human carcinomas, and these studies have shown that the MT are often upregulated in malignant compared to normal cells. Furthermore it has been shown, that upregulated MT associates with high-grade histology and an aggressive behavior in many types of carcinoma. 5 By contrast, very limited information is available about MT expression in lymphoma.
Thus to data, only 2 previous reports of a total of 12 lymphomas of different subtypes are available. 7, 25 In an attempt to investigate whether MT have implications in lymphoma, we have examined MT mRNA and protein expression in mature B-cell lymphomas with particular reference to diffuse large B-cell lymphoma (DLBCL), which constitutes the most frequent subtype of B-cell lymphoma in Western countries. Although classified as one disease the REAL and WHO classifications, 26 several more recent investigations have indicated that DLBCL is likely to encompass more than one biological entity. Thus is has been shown that different clinical subtypes can be recognized by phenotypic and genotypic investigations at the protein, mRNA and DNA level. [27] [28] [29] For example, it has been shown in this and other laboratories that at the least three subgroups with different outcomes can been distinguished depending upon the mRNA expression profiles. For personal use only. on September 13, 2017. by guest www.bloodjournal.org From generally shows an indolent course, the behavior of the ABC and type-3 lesions is more aggressive. 15, 18, 19, [30] [31] [32] Here we show that mRNA encoding MT-I and MT-II is differentially upregulated in half of DLBCL with an ABC signature and in one third of type-3 tumours, but is low to undetectable in DLBCL with a GCB signature. Furthermore, it is shown that upregulated MT-I and II mRNA in DLBCL correlates with treatment failure and a short survival. This was evident both in this series and in another two independent data sets published by Rosenwald et al. (2002) 16 and Monti et al (2005) . 17 Since the genes encoding MT-I and II are not contained in either our or other previously reported classifier lists for distinction between ABC and GCB DLBCL, 15 Very few previous reports have specifically addressed the MT mRNA and protein levels in lymphomas, and it is presently not clear how the MT influence the behavior of DLBCL at the molecular level. One obvious possibility is that enhanced MT can confer resistance to conventional chemotherapies commonly used in treating DLBCL, e.g. antracyclins and cyclophophamide. 23, 24 Indeed, studies have shown that MT can inhibit anthracyclin induced mitochondrial cytochrome c release and caspase-3 activation, 33, 34 and can mediate intracellular sequestration of cyclophophamide. 35, 36 Thus it is possible that upregulated MT mRNA and protein may identify a particular subgroup of DLBCL, which could benefit from more intensive therapy and/or from other treatment modalities than conventional CHOP or CHOP-like regimens. Potentially interesting options in this respect are electron-affinic compounds such as Motexafin gadolinium, which increases oxidative stress, enhances expression of metal response element-binding transcription factor-1 regulated genes, including MT, and can induced cell cycle arrest and apoptosis in B-cell lines in vitro under appropriate conditions. 37 Since cells may be more susceptible if already subjected to oxidative stress, both
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From the MT high DLBCL described in this report and the recently identified so-called OxPhos consensus cluster of DLBCL, characterized by increased levels of several genes associated with oxidative phosphorylation, 17 could constitute interesting targets for future investigations in clinical trials.
In a previous study it has been suggested that MT may constitute a "malignancy marker" in B-cell lymphomas based on the observation that tumour infiltrating lymphocytes in 11 gastro-intestinal tract lymphomas were MT-negative, unlike the lymphoma cells which were positive to varying extends. 25 The results from this investigation support the view that tumour-infiltrating lymphocytes in B-cell lymphomas are generally MT-negative. However, it is also shown that MT protein in these conditions is not confined to the lymphoma cells, but that a proportion of tumour infiltrating macrophages are often MT-positive, especially in DLBCL.
Since no specific correlation was identified between the number of MT-positive macrophages and lymphoma cells in this series, the observed MT-staining of macrophages presumably did not result from phagocytosis, but rather reflected endogenous synthesis. In keeping with this assumption are the observations that MT can be induced in monocytes under in vitro conditions and that MT-positive macrophages are also recruited to mice brain tissue subjected to cryoinjury. 38, 39 The functional implications of the MT-positive tumour infiltrating macrophages seen in this study and the stimuli, which induce them is not known. Interestingly, in this report the proportion of MT-positive macrophages in DLBCL did not seem to influence the survival although they correlated with and presumably contributed to the MT mRNA levels measured in crude extracts. Hence, from a clinical perspective, it is recommended that MT measurements of crude extracts be supplemented with immunohistological assessments, which permit distinction between MT-positive lymphoma cells and macrophages.
In conclusion, it is suggested that upregulated MT-I and MT-II mRNA and increased MT-I and MT-II protein expression by the lymphoma cells constitute independent risk factors in DLBCL. How the MT influence the behavior of DLBCL at the molecular level is unknown. However, it is tempting to assume that increased proliferation, decreased apoptosis and increased acquisition of resistance to chemotherapy may be implicated. These issues will be important to address in future investigations. For personal use only. on September 13, 2017. by guest www.bloodjournal.org From For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From
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